Twist Bioscience Q1 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported fiscal 2026 first-quarter results that absorption said extended a multi-year inclination of accordant execution, highlighting its 12th consecutive 4th of gross maturation and continued advancement toward profitability. On the company’s net call, executives emphasized accelerating request tied to AI-enabled discovery, improving manufacturing economics, and accrued concern successful commercialized and integer capabilities portion reiterating a people of adjusted EBITDA break-even successful the 4th fourth of fiscal 2026.

CFO Adam Laponis said first-quarter gross roseate to $103.7 million, representing 17% year-over-year growth and astir 5% sequential growth. Gross borderline was 52.0%, which Laponis said came successful higher than expected and reflected gross maturation and continuous process improvements. Operating expenses excluding outgo of revenues were $86.9 million, up from $77.5 million successful the year-ago period, driven by investments successful commercialized groups and integer capabilities.

→ Palantir Bulls Face a Reality Check Before Earnings

Adjusted EBITDA was a nonaccomplishment of approximately $13.4 million, an betterment of about $2.8 million versus the prior-year quarter. Net currency utilized successful operating activities was $24.8 million, superior expenditures were $10 million, and the institution ended the 4th with $197.9 million successful cash, currency equivalents, and short-term investments.

CEO and co-founder Dr. Emily Leproust said the quarter’s show built connected operating momentum from fiscal 2025 and reflected trends she believes stay intact. Leproust and President/COO Dr. Patrick Finn focused overmuch of their prepared remarks and Q&A connected Twist’s efforts to service what they described arsenic a rapidly forming marketplace successful AI-enabled therapeutics discovery.

→ MarketBeat Week successful Review – 01/26 - 01/30

Laponis reported that DNA synthesis and macromolecule solutions (DSPS) gross accrued to $51.1 million, up 27% twelvemonth implicit year, and said the maturation was driven by customers pursuing AI-enabled discovery. Leproust said the institution had booked more than $25 million successful orders tied specifically to AI find successful fiscal 2025, describing those orders arsenic “backloaded,” with immoderate orders received successful the 4th fourth shipping successful the archetypal quarter. In effect to expert questions, she said customers with ample orders successful anterior quarters were returning with further ample orders, and that Twist was besides adding much ample pharma, “the Magnificent Seven,” and well-funded startups.